CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model

Clinical and Experimental Metastasis

Volumn 31, Issue 7, 2014, Pages 829-839

  Domanska, Urszula M ^a   Boer, Jennifer C ^a   Timmer Bosscha, Hetty ^a   van Vugt, Marcel A T M ^a   Hoving, Hilde D ^a   Kliphuis, Nathalie M ^a   Rosati, Stefano ^a   van der Poel, Henk G ^b   de Jong, Igle Jan ^a   de Vries, Elisabeth G E ^a   Walenkamp, Annemiek M E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

AMD3100; CXCR4; Radiosensitivity; Tumor cell mobilization

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; PLERIXAFOR; CXCR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RADIOTHERAPY; CELL CULTURE; CELL MOTILITY; CELL SURVIVAL; CELL VIABILITY ASSAY; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; LNCAP CELL LINE; LYMPH NODE METASTASIS; MALE; METASTASIS; MONOCULTURE; MOUSE; NONHUMAN; PROSTATE CANCER; RADIATION DOSE; RADIOSENSITIVITY; STROMA CELL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANIMALS; DISEASE MODELS, ANIMAL; MALE; MICE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RECEPTORS, CXCR4;

EID: 84910135124     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-014-9673-2     Document Type: Article

References (44)

1. Kuonen F, Secondini C, Rüegg C (2012) Molecular Pathways: emerging Pathways Mediating Growth, Invasion, and Metastasis of Tumors Progressing in an Irradiated Microenvironment. Clin Cancer Res 18:5196–5202
2. Kozin SV, Duda DG, Munn LL et al (2012) Neovascularization After Irradiation: what is the Source of Newly Formed Vessels in Recurring Tumors? J Natl Cancer Inst 104:899–905
3. Yoshimura M, Itasaka S, Harada H et al (2013) Microenvironment and Radiation Therapy. BioMed Res Int 2013:13
4. Ponomaryov T, Peled A, Petit I et al (2000) Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 106:1331–1339
5. Kioi M, Vogel H, Schultz G et al (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120:694–705
6. Barcellos-Hoff M, Park C, Wright EG (2005) Radiation and the microenvironment—tumorigenesis and therapy. Nat Rev Cancer 5:867–875
7. Ou D, Chen C, Lin S et al (2006) Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy. J Pathol 210:363–373
8. Taichman RS, Cooper C, Keller ET et al (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832–1837
9. Chinni SR, Sivalogan S, Dong Z et al (2006) CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 66:32–48
10. Domanska UM, Timmer-Bosscha H, Nagengast WB et al (2012) CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 14:709–718
11. Shiozawa Y, Pedersen EA, Havens AM et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121:1298–1312
12. Porvasnik S, Sakamoto N, Kusmartsev S et al (2009) Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 69:1460–1469
13. Petit I, Szyper-Kravitz M, Nagler A et al (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3:687–694
14. Broxmeyer HE, Cooper S, Kohli L et al (2003) Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol 170:421–429
15. Lee Y, Gotoh A, Kwon H et al (2002) Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. Blood 99:4307–4317
16. Meads MB, Hazlehurst LA, Dalton WS (2008) The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14:2519–2526
17. Meads MB, Gatenby RA, Dalton WS (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9:665–674
18. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71
19. Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572–583
20. Klotz L, Zhang L, Lam A et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131
21. Singh S, Singh UP, Grizzle WE et al (2004) CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 84:1666–1676
22. Zhuo W, Jia L, Song N et al (2012) The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis. Clin Cancer Res 18:5387–5398
23. De Klerck B, Geboes L, Hatse S et al (2005) Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Res Ther 7:1208–1220
24. Sanchez-Martin L, Estecha A, Samaniego R et al (2011) The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117:88–97
25. Hatse S, Princen K, Bridger G et al (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527:255–262
26. Matthys P, Hatse S, Vermeire K et al (2001) AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 167:4686–4692
27. Giubellino A, Woldemichael GM, Sourbier C et al (2012) Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. Cancer Lett 316:46–52
28. DiPersio JF, Uy GL, Yasothan U et al (2009) Plerixafor. Nat Rev Drug Discov 8:105–107
29. Rettig MP, Ansstas G, DiPersio JF (2012) Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 26:34–53
30. Galsky MD, Vogelzang NJ, Conkling P et al (2014) A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res 20:3581–3588
31. Muller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56
32. Smith MC, Luker KE, Garbow JR et al (2004) CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64:8604–8612
33. Huang EH, Singh B, Cristofanilli M et al (2009) A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155:231–236
34. Uchida D, Onoue T, Kuribayashi N et al (2011) Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur J Cancer 47:452–459
35. Wong D, Kandagatla P, Korz W et al (2014) Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. BMC Urol 14:12
36. Nervi B, Ramirez P, Rettig MP et al (2009) Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113:6206–6214
37. Dillmann F, Veldwijk MR, Laufs S et al (2009) Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL + cell to Imatinib and Nilotinib. Leuk Lymphoma 50:1676–1686
38. Hassan S, Buchanan M, Jahan K et al (2010) CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 129:225–232
39. Weekes CD, Song D, Arcaroli J et al (2012) Stromal cell-derived factor 1 mediates resistance to mTOR-directed therapy in pancreatic Cancer. Neoplasia 14:690–701
40. Schmid MC, Avraamides CJ, Foubert P et al (2011) Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Res 71:6965–6975
41. Kozin SV, Kamoun WS, Huang Y et al (2010) Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 70:5679–5685
42. Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339:286–291
43. Kalatskaya I, Berchiche YA, Gravel S et al (2009) AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 75:1240–1247
44. McGinn OJ, Marinov G, Sawan S et al (2012) CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein. J Cell Sci 125:5467–5478